A new vaccine has been approved for use in the United States to reduce the risk of herpes zoster (shingles) in older adults.
The vaccine was approved for licensing on May 26 by the US Food and Drug Administration (FDA) and is indicated for patients aged 60 years or older without compromised immune systems. It is expected to reduce by about 50% the risk of shingles, which is caused by a reactivation of the virus (varicella zoster) responsible for chickenpox.
Mitka M. FDA Approves Shingles Vaccine. JAMA. 2006;296(2):157–158. doi:10.1001/jama.296.2.157
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: